TransThera Sciences (Nanjing). Inc. (HK:2617)
:2617
Want to see HK:2617 full AI Analyst Report?
Total Valuation
TransThera Sciences (Nanjing). Inc. has a market cap or net worth of HK$10.63B. The enterprise value is HK$0.00.
Market CapHK$10.63B
Enterprise ValueHK$0.00
Share Statistics
TransThera Sciences (Nanjing). Inc. has 312,687,680 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding312,687,680
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
TransThera Sciences (Nanjing). Inc.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee0.00
Profits Per Employee-2.45M
Employee Count121
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of TransThera Sciences (Nanjing). Inc. is ―. TransThera Sciences (Nanjing). Inc.’s PEG ratio is -13.39.
PE Ratio―
PS Ratio0.00
PB Ratio96.58
Price to Fair Value96.58
Price to FCF-158.52
Price to Operating Cash Flow-101.36
PEG Ratio-13.39
Income Statement
In the last 12 months, TransThera Sciences (Nanjing). Inc. had revenue of 0.00 and earned -295.96M in profits. Earnings per share was -0.76.
Revenue0.00
Gross Profit0.00
Operating Income-300.18M
Pretax Income-295.96M
Net Income-295.96M
EBITDA-290.82M
Earnings Per Share (EPS)-0.76
Cash Flow
In the last 12 months, operating cash flow was -106.74M and capital expenditures -179.00, giving a free cash flow of -277.66K billion.
Operating Cash Flow-106.74M
Free Cash Flow-277.66K
Free Cash Flow per Share>-0.01
Dividends & Yields
TransThera Sciences (Nanjing). Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.68
52-Week Price Change30.50%
50-Day Moving Average161.63
200-Day Moving Average―
Relative Strength Index (RSI)56.52
Average Volume (3m)4.21M
Important Dates
TransThera Sciences (Nanjing). Inc. upcoming earnings date is Mar 31, 2026, Before Open (Confirmed).
Last Earnings DateAug 25, 2025
Next Earnings DateMar 31, 2026
Ex-Dividend Date―
Financial Position
TransThera Sciences (Nanjing). Inc. as a current ratio of 3.87, with Debt / Equity ratio of 0.40%
Current Ratio3.87
Quick Ratio3.87
Debt to Market Cap0.00
Net Debt to EBITDA―
Interest Coverage Ratio-2.48K
Taxes
In the past 12 months, TransThera Sciences (Nanjing). Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
TransThera Sciences (Nanjing). Inc. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
TransThera Sciences (Nanjing). Inc. has HK$489.14M in cash and marketable securities with HK$1.65M in debt, giving a net cash position of HK$487.49M billion.
Cash & Marketable SecuritiesHK$489.14M
Total DebtHK$1.65M
Net CashHK$487.49M
Net Cash Per ShareHK$1.56
Tangible Book Value Per ShareHK$1.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for TransThera Sciences (Nanjing). Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―